

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 038 957 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

27.09.2000 Bulletin 2000/39

(51) Int. Cl.<sup>7</sup>: **C12N 15/12, C07K 14/435,  
C07K 16/18**

(21) Application number: **98955925.7**

(86) International application number:

**PCT/JP98/05306**

(22) Date of filing: **25.11.1998**

(87) International publication number:

**WO 99/28457 (10.06.1999 Gazette 1999/23)**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

(72) Inventors:

- **HARADA, Yosuke**  
Tokushima-shi, Tokushima 770-0868 (JP)
- **OZAKI, Kouichi,**  
Ribasaido Minamisuehiro  
Tokushima-shi, Tokushima 770-0865 (JP)

(30) Priority: **28.11.1997 JP 34378997**

**20.04.1998 JP 12680398**

(74) Representative: **Marsh, Roy David**

**Hoffmann Eitle,  
Patent- und Rechtsanwälte,  
Arabellastrasse 4  
81925 München (DE)**

(71) Applicant:

**OTSUKA PHARMACEUTICAL CO., LTD.  
Chiyoda-ku, Tokyo 101-0048 (JP)**

(54) **TSA305 GENE**

(57) The invention provides a pancreas-specific gene comprising a base sequence coding for the amino acid sequence shown under SEQ ID NO:1, which gene is effective particularly in the fields of study, diagnosis and treatment, among others, of pancreatic carcinoma.

**EP 1 038 957 A1**

**Description****TECHNICAL FIELD**

**[0001]** The present invention relates to a gene, named TSA305, coding for a protein specifically expressed in the pancreas and, more particularly, to the above pancreas-specific gene having a high level of homology with nematode sel-1 and expected to show an anticancer activity. The invention also relates to a novel protein encoded by such gene and to a specific antibody thereto.

**BACKGROUND ART**

**[0002]** Pancreatic cancer holds the fourth and fifth place on the list of cancer-related deaths in Japan and western countries, respectively and has the worst prognosis among digestive system malignancies (Poston, J. G., et al., Gut, 32, 800-812 (1991)). The ultimate goal in cancer research is to discriminate early stage gene changes leading to malignant transformation. If such changes can be differentiated, genetic tools for early diagnosis may possibly be developed and novel therapeutic approaches for more effective treatment of this lethal disease will possibly be taken.

**[0003]** Meanwhile, the nematode sel-1 gene reportedly has an inhibitory action on Notch/lin-12 which suppresses the differentiation of ectoderm into neuroblast in neural development in nematodes (Genetics, 143 (1), 237-247 (1996); Development, 124 (3), 637-644 (1997)). Said Notch/lin-12, when forcedly expressed, causes breast cancer or leukemia and therefore is considered to be a cancer-related gene. The above sel-1 gene suppressively acting on said cancer-related gene is therefore considered to suppressively act on cancer as well. At present, however, the roles of these genes have not been fully elucidated.

**[0004]** Elucidation of the physiological roles of such genes and the information obtained therefrom are important in elucidating the mechanisms of onset of diseases such as malignant transformation and inflammation and are desired not only in the field of basic scientific studies but also in the pharmaceutical field in determining the causes of such diseases as cancer and inflammation and developing treatment methods for such diseases.

**DISCLOSURE OF INVENTION**

**[0005]** The present invention has for its object to provide the above information desired in the relevant field of art, in particular a gene coding for a novel protein homolog and having homology with the sel-1 gene.

**[0006]** With that object in view, the present inventors made an arduous search among genes derived from various human tissues and, as a result, succeeded in newly isolating and identifying a gene coding for a protein specifically expressed in the pancreas and found that the above object can be realized with said gene. As a result, the present invention has now been completed.

**[0007]** Thus, the present invention provides a pancreas-specific gene, TSA305, comprising a nucleotide sequence coding for a protein having the amino acid sequence shown under SEQ ID NO:1, in particular the TSA305 gene which is a human gene.

**[0008]** The invention also provides a pancreas-specific protein (TSA305 protein) comprising the amino acid sequence shown under SEQ ID NO:1 and an antibody capable of coupling therewith.

**[0009]** The invention further provides a pancreas-specific gene, TSA305, which is a polynucleotide defined below under (a) or (b) in particular to the TSA305 gene which is a human gene:

(a) A polynucleotide comprising the whole or part of the nucleotide sequence shown under SEQ ID NO:2.

(b) A polynucleotide capable of hybridizing with a DNA having the nucleotide sequence shown under SEQ ID NO:2 under stringent conditions.

**[0010]** In addition, the present invention provides the above gene in DNA fragment form which is useful as a specific probe or specific primer for gene detection.

**[0011]** In expressing amino acids, peptides, nucleotide sequences, nucleic acids and the like by abbreviations or symbols in the following, the nomenclature of the IUPAC-IUB [IUPAC-IUB Communication on Biological Nomenclature, Eur. J. Biochem., 138: 9 (1984)], the "Guideline for preparing specifications etc. containing nucleotide sequences or amino acid sequences" (edited by the Patent Office of Japan) and the conventional symbols in the relevant field are followed or used.

**[0012]** As a specific example of the gene of the invention, there may be mentioned the one deduced from the DNA sequence of a PCR product named "TSA305" which is to be shown later in the example section. The nucleotide sequence thereof is as shown under SEQ ID NO:3.

**[0013]** Said gene is a human cDNA containing a coding region having the nucleotide sequence shown under SEQ

ID NO:2 and coding for a novel pancreas-specific protein (hereinafter referred to as TSA305 protein) composed of 794 amino acid residues as shown under SEQ ID NO:1 and is composed of a total length of 7,885 nucleotides.

[0014] As a result of searching in the GenBank/EMBL database utilizing the FASTA program (Person, W. R., et al., Proc. Natl. Acad. Sci. USA, 85, 2444-2448 (1988)), it was confirmed that the product of expression of the TSA305 gene of the invention, namely the TSA305 protein, has a very high level of homology with the nematode sel-1 gene (cf. the reference cited above). In view of this fact, it is considered that the gene of the invention, like the above-mentioned set-1, act suppressively on Notch/lin-12 which is a cancer-related gene considered to be involved in embryogenesis in general.

[0015] The locus of the gene of the invention is q24.3-q31.1 of the 14th chromosome where a gene causative of insulin-dependent diabetes mellitus (IDDM) is considered to exist. In view of this fact, it is strongly suggested that the gene of the invention be related with diabetes.

[0016] It was further revealed that the product of expression of the gene of the invention is a protein containing a fibronectin type II collagen binding domain. Such collagen binding site close to the N terminal suggests involvement of the protein in fibrogenesis and, based on this, it is strongly suggested that the gene of the invention be involved in fibrosis.

[0017] In addition, since all of the pancreatic carcinoma preparations tested showed a failure of expression of the gene of the invention and the gene is expressed mainly in normal pancreases, it is suggested that the gene of the invention be potentially valuable in forecasting malignant transformation.

[0018] Thus, information and means very useful in elucidating, understanding, diagnosing, preventing and treating various diseases such as mammary cancer, leukemia, fibrosis, diabetes and pancreatic carcinoma, in particular pancreatic carcinoma, are given as a result of providing the TSA305 gene and the product of its expression according to the present invention. The gene of the invention can judiciously be used also in developing a novel drug inducing the expression of the gene of the invention which is utilizable in the treatment of various diseases such as mentioned above. Furthermore, detection of the expression of the gene of the invention or the product of its expression in an individual animal or a specific tissue or detection of a mutation (deletion or point mutation) of said gene or abnormal expression thereof, for instance, is considered to be utilizable adequately in elucidating or diagnosing the above diseases.

[0019] The gene of the invention is specifically represented by a gene containing a nucleotide sequence coding for a protein having the amino acid sequence shown under SEQ ID NO:1 or a gene which is a polynucleotide containing the nucleotide sequence shown under SEQ ID NO:2. However, the gene of the invention is not particularly limited to these but may be, for example, a gene leading to a certain modification in the above specific amino acid sequence or a gene having a certain level of homology with the above specific nucleotide sequence.

[0020] Thus, the gene of the invention also includes a gene containing a nucleotide sequence coding for a protein having an amino acid sequence derived from the amino acid sequence shown under SEQ ID NO:1 by deletion, substitution or addition of one or a plurality of amino acid residues and having the same activity as that of TSA305. The extent and site(s) of "deletion, substitution or addition of an amino acid residue or residues" are not particularly restricted if the modified protein is a product of the same effect which has the same function as the protein having the amino acid sequence shown under SEQ ID NO:1. The term "plurality" used above means 2 or more, normally several.

[0021] While the modification (mutation) or the like of the above amino acid sequence may occur naturally, for example by mutation or posttranslational modification, artificial modification is also possible based on a nature-derived gene (for example, a specific example of the gene of the present invention). The present invention covers all modified genes having the above characteristic without reference to the cause and means, among others, of such modification or mutation.

[0022] As examples of the above artificial means, there may be mentioned site-specific mutagenesis [Methods in Enzymology, 154: 350, 367-382 (1987); *ibid.*, 100: 468 (1983); Nucleic Acids Res., 12: 9441 (1984); Zoku Seikagaku Jikken Koza (Experiments in Biochemistry, second series) 1: "Idensi Kenkyuho (Methods in Gene Research) II", edited by the Biochemical Society of Japan, p. 105 (1986)] and other genetic engineering techniques, means of chemical synthesis such as the phosphotriester method or phosphoamidite method [J. Am. Chem. Soc., 89: 4801 (1967); *ibid.*, 91: 3350 (1969); Science, 150: 178 (1968); Tetrahedron Lett., 22: 1859 (1981); *ibid.*, 24: 245 (1983)], and combinations thereof.

[0023] In a mode of embodiment of the gene of the present invention, there may be mentioned a gene which is a polynucleotide containing the whole or part of the nucleotide sequence shown under SEQ ID NO:3. The open reading frame (nucleotide sequence shown under SEQ ID NO:2) containing in this nucleotide sequence also serves as an example of combination of codons specifying respective amino acid residues in the above amino acid sequence (SEQ ID NO:1). The gene of the invention is not limited to this but can of course have a nucleotide sequence in which an arbitrary combination of codons is selected. The selection of codons can be made in the conventional manner, for example the codon usage in the host employed, among others, can be taken into consideration [Nucleic Acids Res., 9: 43 (1981)].

[0024] While the gene of the invention is represented in terms of single strand DNA nucleotide sequence, as

shown, for example, under SEQ ID NO:2, the invention of coarse includes a polynucleotide having a nucleotide sequence complementary to such nucleotide sequence, or a component comprising both of these as well. It is not limited to a DNA such as a cDNA.

[0025] Furthermore, as mentioned above, the gene of the invention is not limited to a polynucleotide containing the whole or part of the nucleotide sequence shown under SEQ ID NO:2, but includes genes comprising a nucleotide sequence having a certain level of homology with said nucleotide sequence as well. As such genes, there may be mentioned those at least capable of hybridizing with a DNA comprising the nucleotide sequence shown under SEQ ID NO:2 under such stringent conditions as mentioned below and incapable of being released therefrom even by washing under certain conditions.

[0026] Thus, mention may be made, as an example, of a gene having a nucleotide sequence which hybridizes with a DNA having the nucleotide sequence shown under SEQ ID NO:2 under conditions: at 65°C overnight in 6 × SSC or at 37°C overnight in 4 × SSC containing 50% formamide and is not released from said DNA under washing conditions: 30 minutes at 65°C with 2 × SSC. Here, "SSC" means standard saline citrate; 1 × SSC = 0.15 M NaCl, 0.015 M sodium citrate).

[0027] The gene of the present invention can be produced and recovered with ease by general genetic engineering techniques [see, for example, Molecular Cloning, 2nd Ed., Cold Spring Harbor Lab. Press (1989); Zoku Seikagaku Jikken Koza (Experiments in Biochemistry, second series) "Idenshi Kenkyuho (Methods in Gene Research) I, II and III", edited by the Biochemical Society of Japan (1986)] based on the information on the sequence of a typical example thereof.

[0028] Specifically, the production/recovery can be carried out by constructing a cDNA library in the conventional manner from an appropriate origin in which the gene of the invention is expressed and selecting a desired clone therefrom using an appropriate probe or antibody specific to the gene of the invention [Proc. Natl. Acad. Sci. USA, 78: 6613 (1981); Science, 222: 778 (1983)].

[0029] As examples of the origin of cDNA in the above process, there may be mentioned various cells and tissues in which the gene of the invention is expressed, cultured cells derived therefrom and the like, in particular the pancreatic tissue. Isolation of total RNA from these, isolation and purification of mRNA, obtainment of cDNA and cloning thereof, among others, can all be performed in the conventional manner. cDNA libraries are also commercially available and such cDNA libraries, for example various cDNA libraries commercially available from Clontech Lab. Inc. can also be used in the practice of the present invention.

[0030] The method of screening the cDNA library for the gene of the invention is not particularly restricted but may be a conventional one. As specific examples, there may be mentioned the method comprising selecting the corresponding cDNA clone by immunological screening using a specific antibody to the protein produced by the cDNA, plaque hybridization or colony hybridization using a probe selectively binding to the desired DNA sequence, and combinations of these.

[0031] As examples of the probe to be used here, there may generally be mentioned DNAs chemically synthesized based on the information on the nucleotide sequence of the gene of the invention, among others. Of course, it is also possible to successfully utilize the gene of the invention already obtained as such or fragments thereof.

[0032] The screening for the gene of the invention can also be made by the protein interaction cloning procedure using the TSA305 protein in lieu of the above specific antibody and, further, the screening method comprising using, as a screening probe, a sense or antisense primer designed based on the information on the nucleotide sequence of the gene of the invention can also be employed.

[0033] In accordance with the present invention, the mRNA expression levels in cells under different conditions or a plurality of different cell groups can be directly compared and investigated by the differential display technique (Liang, P., et al., Science, 257: 967-971 (1992)).

[0034] In obtaining the gene of the present invention, DNA/RNA amplification by the PCR technique [Science, 230: 1350 (1985)] can judiciously be utilized. In particular, in cases where it is difficult to obtain the full-length cDNA from a library, the RACE technique (rapid amplification of cDNA ends; Jikken Igaku (Experimental Medicine), 12 (6): 35 (1994)), in particular the 5'-RACE technique [Proc. Natl. Acad. Sci. USA, 85: 8998 (1988)], for instance, is judiciously employed. The primers to be used when such PCR technique is employed can be adequately designed based on the information on the sequence of the gene of the invention as revealed by the present invention and can be synthesized in the conventional manner.

[0035] The amplified DNA/RNA fragments can be isolated and purified in the conventional manner, as mentioned above, for example by gel electrophoresis.

[0036] The gene of the invention or various DNA fragments obtained in the above manner can be sequenced in the conventional manner, for example by the dideoxy method [Proc. Natl. Acad. Sci. USA, 74: 5463 (1977)] or the Maxam-Gilbert method [Methods in Enzymology, 65: 499 (1980)] or, in a simple and easy manner, by using a commercial sequencing kit or the like.

[0037] By utilizing the gene of the present invention, it is possible to readily produce the corresponding gene prod-

uct stably in large amounts by using general genetic engineering techniques. Therefore, the present invention also provides a vector (expression vector) containing the TSA305 gene of the invention, host cells transformed with said vector and a method of producing the TSA305 protein which comprises cultivating said host cells.

[0038] The production method can be carried out according to the ordinary recombinant DNA technology [see, for example, Science, 224: 1431 (1984); Biochem. Biophys. Res. Comm., 130: 692 (1985); Proc. Natl. Acad. Sci. USA, 80: 5990 (1983); and the references cited above].

[0039] Both prokaryotes and eukaryotes can be used as the host cells mentioned above. As prokaryotic hosts, there may be mentioned a wide variety of ones in general use, such as Escherichia coli, Bacillus subtilis, etc., and preferred examples are those included among Escherichia coli strains, in particular the Escherichia coli K 12 strain. The eukaryotic host cells include vertebrate cells and yeast cells, among others. As the former, COS cells [Cell, 23: 175 (1981)], which are simian cells, chinese hamster ovary cells and the dihydrofolate reductase-deficient strain thereof [Proc. Natl. Acad. Sci. USA, 77: 4216 (1980)], for instance, are judiciously used and, as the latter, yeast cells belonging to the genus Saccharomyces and the like are judiciously used. Of course, the host cells are not limited to these.

[0040] Where prokaryotic cells are used as the host, an expression plasmid can judiciously be used which is constructed using a vector capable of replicating in said host cells and providing this vector with a promoter and the SD (Shine and Dalgarno) sequence upstream of the gene of the invention and further with an initiation codon (e.g. ATG) necessary for the initiation of protein synthesis so that the gene of the invention may be expressed. Often used as the above vector are generally Escherichia coli-derived plasmids, for example pBR322, pBR325, pUC12 and pUC13. The vector is not limited to these, however, but various known vectors may be utilized. As commercially available vectors of the above kind which can be used in expression systems in which Escherichia coli is used, there may be mentioned, for example, pGEX-4T (Amersham Pharmacia Biotech), pMAL-C2, pMAL-P2 (New England Biolabs), pET21, pET21/lacq (Invitrogen) and pBAD/His (Invitrogen).

[0041] As the expression vector in the case of vertebrate cells being used as the host, there may be mentioned one generally having a promoter located upstream of the gene of the invention which is to be expressed, an RNA splicing site, a polyadenylation site and transcription termination sequence. When necessary, this may further have an origin of replication. As specific examples of said expression vector, there may be mentioned pSV2dhfr having the early promoter of SV40 [Mol. Cell. Biol., 1: 854 (1981)] and the like. In addition to the above, various known commercial vectors can also be used. As commercial vectors of such kind which are to be utilized in expression systems in which animal cells are used, there may be mentioned, among others, vectors for animal cells, such as pEGFP-N, pEGFP-C (Clontech), pIND (Invitrogen) and pcDNA3.1/His (Invitrogen), and vectors for insect cells, such as pFastBac HT (Gibco BRL), pAcGHLT (PharMingen), pAc5/V5-His, pMT/V5-His and pMT/Bip/V5-His (the latter three: Invitrogen).

[0042] As specific examples of the expression vector to be used when yeast cells are used as the host, there may be mentioned, among others, pAM82 having a promoter for the acid phosphatase gene [Proc. Natl. Acad. Sci. USA, 80: 1 (1983)] and the like. Commercial expression vectors for yeast cells include, among others, pPICZ (Invitrogen) and pPICZ $\alpha$  (Invitrogen).

[0043] The promoter is not particularly restricted, either. When an Escherichia species is used as the host, the tryptophan (trp) promoter, lpp promoter, lac promoter, recA promoter, PL/PR promoter or the like can judiciously be utilized. When the host is a Bacillus species, the SP01 promoter, SP02 promoter, penP promoter or the like is preferred. As for the promoter to be used when a yeast species is the host, the pH05 promoter, PGK promoter, GAP promoter or ADH promoter, for instance, can judiciously be used. As preferred examples of the promoter to be used when animal cells are used as the host, there may be mentioned SV40-derived promoters, retrovirus promoters, and the metallothionein promoter, heat shock promoter, cytomegalovirus promoter and SR $\alpha$  promoter.

[0044] Conventional fused protein expression vectors can also judiciously be used as the expression vector for the gene of the present invention. As specific examples of such vectors, there may be mentioned pGEX (Promega) for the expression of a protein fused with glutathione-S-transferase (GST) and the like.

[0045] The method of introducing the desired recombinant DNA (expression vector) into host cells for transforming the same is not particularly restricted, either, but various general methods can be employed. The transformant obtained can be cultivated in the conventional manner, whereby the desired TSA305 protein encoded by the gene of the present invention is expressed/produced and accumulated or secreted within or outside the transformant cells or on the cell membrane.

[0046] The medium to be used in the above cultivation can adequately be selected from among various conventional ones according to the host cells employed, and the cultivation can be conducted under conditions suited for the growth of the host cells.

[0047] The thus-obtained recombinant protein (TSA305 protein) can be isolated and purified, as desired, by various separation procedures utilizing its physical and/or chemical properties, among others [see, for example, "Seikagaku (Biochemical) Data Book II", pages 1175-1259, 1st edition, 1st printing, published June 23, 1980 by Tokyo Kagaku Dojin; Biochemistry, 25 (25): 8274 (1986); and Eur. J. Biochem., 163: 313 (1987)]. As said methods, there may specifically be mentioned, for example, ordinary reconstitution treatment, treatment with a protein precipitating agent (salting

out), centrifugation, osmotic shock procedure, sonication, ultrafiltration, various chromatographic techniques such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography and high-performance liquid chromatography (HPLC), dialysis and combinations of these. Particularly preferred among the above methods is affinity chromatography using a column to which a specific antibody to the TSA305 protein of the invention is bound.

[0048] Thus, the present invention further provides the novel TSA305 protein itself as obtained, for example, in the above manner. As mentioned hereinabove, said protein has a high level of homology with the nematode sel-1 and can produce an inhibitory effect on various kinds of cancer and therefore useful in the pharmaceutical field.

[0049] This TSA305 protein can also be utilized as an immunogen for producing an antibody specific to said protein. The component to be used here as the antigen may be the protein mass-produced by the genetic engineering techniques mentioned above or a fragment thereof, for instance. By utilizing such antigen, it is possible to obtain the desired antiserum (polyclonal antibody) or monoclonal antibody. The methods of producing said antibody are themselves well known to those skilled in the art and, in the practice of the present invention as well, these conventional methods can be followed [see, for example, Zoku Seikagaku Jikken Koza (Experiments in Biochemistry, second series) "Men-eki Seikagaku kenkyuho (Methods in Immunobiochemistry)", edited by the Biochemical Society of Japan (1986)].

[0050] Thus, for example, the animal to be immunized for obtaining antisera can be arbitrarily selected from among ordinary animals such as rabbits, guinea pigs, rats, mice and chickens, and immunization with the antigen mentioned above, blood collection and other procedures can also be carried out in the conventional manner.

[0051] The monoclonal antibody, too, can be produced in the conventional manner by producing hybrid cells from plasmacytes (immunocytes) of an animal immunized with the immunogen mentioned above and plasmacytoma cells, selecting a desired antibody-producing clone from among them, and cultivating said clone. The animal to be immunized is generally selected taking into consideration the compatibility with the plasmacytoma cells employed for cell fusion and, generally, mice or rats, among others, are advantageously used. The immunization can be conducted in the same manner as in the above-mentioned case of antisera and, if desirable, an ordinary adjuvant or the like may be used in combination.

[0052] The plasmacytoma cells to be used for cell fusion are not particularly restricted but, for example, various myeloma cells such as p3 (p3/x63-Ag8) [Nature, 256: 495-497 (1975)], p3-U1 [Current Topics in Microbiology and Immunology, 81: 1-7 (1978)], NS-1 [Eur. J. Immunol., 6: 511-519 (1976)], MPC-11 [Cell, 8: 405-415 (1976)], SP2/0 [Nature, 276: 269-271 (1978) and the like, R210 in rats [Nature, 277: 131-133 (1979)] and the like as well as cells derived therefrom all can be used.

[0053] The fusion of the above immunocytes and plasmacytoma cells can be performed by a known method in the presence of a conventional fusion accelerator such as polyethylene glycol (PEG) or Sendai virus (HVJ) and the desired hybridomas can also be isolated in the conventional manner [e.g. Meth. in Enzymol., 73: 3 (1981); Zoku Seikagaku Jikken Koza (Experiments in Biochemistry, second series) cited above].

[0054] The desired antibody-producing cell line can be searched for and a monoclonal antibody can be derived therefrom in the conventional manner. Thus, for example, the search for an antibody-producing cell line can be carried out using the above-mentioned antigen of the present invention by various methods generally used in detecting antibodies, such as the ELISA technique [Meth. in Enzymol., 70: 419-439 (1980)], plaque technique, spot technique, agglutination reaction technique, Ouchterlony technique, and radioimmunoassay.

[0055] The antibody of the invention can be collected from the thus-obtained hybridomas, for example, by cultivating said hybridomas in the conventional manner and collecting the culture supernatant or by administering the hybridomas to an animal compatible therewith and, after hybridoma growth, collecting the ascitic fluid. The former method is suited for obtaining a high-purity antibody while the latter method is suited for mass production of an antibody. The thus-obtained antibody can further be purified by conventional means such as salting out, gel filtration and affinity chromatography.

[0056] The thus-obtained antibody is characterized by its ability to bind to the TSA305 protein of the invention and can advantageously be utilized in the above-mentioned purification of the TSA305 protein and in assaying or discriminating the same by immunological techniques. The present invention thus provides such novel antibody as well.

[0057] Further, based on the information on the sequence of the gene of the invention as revealed by the present invention, the expression of the gene of the invention in individuals or in various tissues can be detected, for example by utilizing the whole or part of the nucleotide sequence of said gene.

[0058] Such detection can be carried out in the conventional manner, for example by RNA amplification by RT-PCR [reverse transcribed polymerase chain reaction; E. S. Kawasaki et al., Amplification of RNA. In PCR Protocol, A Guide to methods and applications, Academic Press, Inc., San Diego, 21-27 (1991)], northern blot analysis [Molecular Cloning, Cold Spring Harbor Lab. (1989)], *in situ* RT-PCR [Nucl. Acids Res., 21: 3159-3166 (1993)], *in situ* hybridization or a like technique for assaying the same on the cellular level or by the NASBA technique [nucleic acid sequence-based amplification; Nature, 350: 91-92 (1991)] or other various techniques. All can give good results.

[0059] When the RT-PCR technique is employed, the primers to be used are not limited in any way provided that

they are specific to the gene of the invention and enable specific amplification of said gene alone. The sequences thereof can be adequately designed based on the genetic information according to the present invention. Generally, each may have a partial sequence comprising about 20 to 30 nucleotides.

[0060] In this way, the present invention provides DNA fragments useful as specific primers and/or specific probes in detecting the TSA305 gene according to the invention as well.

#### BRIEF DESCRIPTION OF DRAWINGS

[0061]

Fig. 1 is a photograph, in lieu of a drawing, illustrating the distribution of the gene of the invention in human tissues as examined by the northern blot analysis described in Example 1 under (2).

Fig. 2 is a photograph, in lieu of a drawing, illustrating the results of RT-PCR analysis of normal pancreatic cells and four cell lines as obtained in Example 1 (4). The results for TSA305 are shown in the upper section and the results for  $\beta_2$ -microglobulin as a control are shown in the lower section.

Fig. 3 is a photograph, in lieu of a drawing, illustrating the results of RT-PCR analysis of pancreatic carcinoma samples and others as obtained in Example 1 (5). The results for TSA305 are shown in the upper section and the results for  $\beta_2$ -microglobulin as a control are shown in the lower section.

#### BEST MODE FOR CARRYING OUT THE INVENTION

[0062] The following examples are given for illustrating the present invention in more detail.

##### Example 1

##### (1-1) Method of manifestation by labeling with [ $\alpha$ - $^{33}$ P]ATP

[0063] For identifying the human gene expressed in a tissue-specific process, the method of manifestation by labeling with [ $\alpha$ - $^{33}$ P]ATP was used. The procedure of said method was followed essentially according to the method of Liang (Liang, P., et al., Science, 257: 967-971 (1992)), as mentioned below.

[0064] Thus, polyA RNA (0.2  $\mu$ g) isolated from each of 13 human tissues (adult brain, fetal brain, lung, liver, stomach, pancreas, spleen, mammary gland, bladder, placenta, testis, kidney and heart; products of Clontech) was mixed with 25 pmol of 3'-anchored oligo-dT primer G(T)15MA (M being a mixture of G, A and C) in 8  $\mu$ l of diethyl pyrocarbonate-treated water and the mixture was heated at 65°C for 5 minutes. To this solution were added 4  $\mu$ l of 5 $\times$  First strand buffer (product of BRL), 2  $\mu$ l of 0.1 M DTT (product of BRL), 1  $\mu$ l of 250 mM dNTPs (product of BRL), 1  $\mu$ l of ribonuclease inhibitor (40 units; product of Toyobo) and 1  $\mu$ l of SuperScript II reverse transcriptase (200 units; product of BRL). The final volume of each reaction mixture was 20  $\mu$ l. Each solution was incubated at 37°C for 1 hour and then 2.5-fold diluted by addition of 30  $\mu$ l of distilled water and the dilution was stored at -20°C until the time of use.

[0065] cDNA was amplified by PCR in the presence of [ $\alpha$ - $^{33}$ P]ATP-labeled (product of Amersham) 3'-anchored primer. This cDNA amplification by PCR was conducted in the following manner. Thus, 20  $\mu$ l of each PCR mixture contained 2  $\mu$ l of RT reaction mixture, 2  $\mu$ l of 10 $\times$  PCR buffer (product of Takara), 4  $\mu$ l of 2.5 mM dNTPs, 0.25  $\mu$ l of ExTaq DNA polymerase (5 units/ml; product of Takara), 25 pmol of [ $\alpha$ - $^{33}$ P]ATP-labeled 3'-anchored oligo-dT primer and 25 pmol of 5'-primer (No. 20, decamer deoxyoligo-nucleotide primer having an arbitrary sequence, in this case the nucleotide sequence shown under SEQ ID NO:4). The PCR reaction was carried out under the following conditions. Thus, one cycle was conducted at 95°C for 3 minutes, at 40°C for 5 minutes and at 72°C for 5 minutes, then 40 cycles were conducted each at 95°C for 0.5 minutes, at 40°C for 2 minutes and at 72°C for 1 minute and, finally, the reaction was allowed to proceed at 72°C for 5 minutes.

[0066] Each PCR reaction sample was extracted with ethanol and resuspended in formamide-sequencing dye and the reaction was allowed to proceed on a 6% acrylamide-7.5 M areas sequencing gel. The gel was dried without fixation and autoradiography was carried out overnight.

##### (1-2) Subcloning of the amplified cDNA fragment

[0067] 3MM filter paper with the dried gel placed thereon was marked with radioactive ink in advance. By checking the autoradiogram against this mark, the gel containing the desired cDNA-containing band was excised together with the 3MM filter paper and stirred with 300  $\mu$ l of dH<sub>2</sub>O for 1 hour. After removal of the polyacrylamide gel and filter paper, the cDNA was rerecovered by ethanol precipitation in the presence of 1  $\mu$ l of 10 mg/ml glycogen and 0.3 M NaOAc as a carrier and redissolved in 10  $\mu$ l of dH<sub>2</sub>O. For reamplification, 5  $\mu$ l of this solution was used. The PCR conditions and



primers were the same as those in the first PCR. The reamplification product having an appropriate size was recovered as the first PCR product, and the PCR product was then cloned into the pUC118 vector (product of Takara) at the *HincII* site. The nucleotide sequence was determined using an ABI 377 automated sequencer (product of Applied Biosystems).

[0068] The different patterns manifested upon use of the mRNAs isolated from the 13 human tissues were compared and, as a result, a PCR product specifically expressed in pancreas was identified. This was named TSA305.

[0069] This product was composed of 371 nucleotides. Comparison of the data on this nucleotide with the DNA sequences occurring in the GenBank/EMBL data base using the FASTA program (Person, W. R., et al., Proc. Natl. Acad. Sci. USA, 85: 2444-2448 (1988)) revealed that this PCR product has no homology with any of other known DNA sequences.

### (1-3) cDNA screening

[0070] A human normal pancreas cDNA library was constructed using oligo(dT) + random hexamer-primed human normal pancreas cDNA and Uni-ZAP™ XR (product of Stratagene). The total of  $1 \times 10^6$  clones were isolated by the method mentioned above and subjected to screening using a [ $\alpha$ -<sup>32</sup>P]-dCTP-labeled cDNA fragment. Positive clones were selected and the insert cDNA portions thereof were excised in vivo in pBluescript II SK(-).

[0071] As a result, about 100 plaques were identified as corresponding to TSA305. Based on this result, the percent transcription among all RNAs was calculated to be about 0.01%. The assembled cDNA sequence (TSA305) homologous with TSA305 comprises 7,885 nucleotides containing an open reading frame of 2,382 nucleotides coding for a protein composed of 794 amino acid residues with a calculated molecular weight of 88,768 Da.

[0072] Based on the primary sequence, it was revealed that this gene product (TSA305 protein) is a protein containing a fibronectin type II collagen binding domain.

[0073] The locus thereof was found to be q24.3-q31.1 on the 14th chromosome where a gene causative of insulin-dependent diabetes mellitus (IDDM) is considered to exist.

[0074] The TSA305 gene of the present invention showed a high level of homology with the nematode sel-1.

### (2) Expression in tissues

[0075] For checking the expression profiles of TSA305 in tissues, northern blot analysis was carried out using various human tissues.

[0076] For the northern blot analysis, human MTN (Multiple Tissue Northern) blots I and II (products of Clontech) were used. The cDNA fragments were labeled with [ $\alpha$ -<sup>32</sup>P]-dCTP by PCR using a set of primers with T3 and T7 promoter sequences. The amplification product-containing membrane was prehybridized (the conditions were as indicated in the product protocol), followed by hybridization according to the product protocol.

[0077] After hybridization, the membrane was washed and exposed to an autoradiograph at -80°C for 24 hours. The results are shown in Fig. 1.

[0078] In the figure, the human tissues used were heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes.

[0079] In the figure, a transcript homologous with TSA305 was observed specifically in the pancreas.

### (3) FISH

[0080] FISH was carried out for chromosome arrangement according to a known method (Takahashi, E., et al., Hum. Genet., 86: 14-16 (1990)) using 0.5 µg of each cosmid DNA as a probe. FISH was detected with a Provia 100 film (product of Fuji, ISO 100) or a CCD camera system (Applied Imaging, product of Sightvision).

[0081] As a result, the signals obtained by testing 100 typical cells at (pro)metaphase by R banding were found localized on the bands q24.3-q31.1 of the 14th chromosome. Therefore, the locus of localization of the TSA305 on the chromosome could be identified as 14q24.3-q31.1.

### (4) Expression of transcript in pancreatic carcinoma cell lines and in pancreatic carcinoma tissues as revealed by RT-PCR analysis

[0082] To check whether the expression of the TSA305 gene varies in human pancreatic carcinoma cell lines and pancreatic carcinoma tissues, four cell lines (Aspc1 (metastatic adenocarcinoma; J. Natl. Cancer Inst., 67: 563-569 (1981)), Bxpc3 (adenocarcinoma, undifferentiated; Cancer Invest., 4: 15-23 (1986)), MiaPaca2 (adenocarcinoma; Int. J. Cancer, 19: 128-135 (1977)) and PANC1 (epithelioid, pancreatic duct carcinoma; Int. J. Cancer, 15: 741-747 (1975)) and 9 pancreatic carcinoma tissues (gifts from Dr. Nakamura at the University of Tokyo Institute of Medical Sciences)



were subjected to RT-PCR analysis.

[0083] Thus, 10 µl of the total RNA isolated from each cell line or pancreatic carcinoma tissue using ISOGEN (product of Wako) was treated with 10 units of RNase-free DNase I (product of Boehringer Mannheim) for 15 minutes, followed by two repetitions of extraction with phenol-chloroform and precipitation with ethanol. The single-stranded cDNA was synthesized using Superscript I™ RNase H reverse transcriptase (product of Life Technology) with oligo-d(T) and random primers. A 2-µl portion of each product was used for PCR amplification.

[0084] The primers P1 and P2S having the nucleotide sequences shown under SEQ ID NO:5 and SEQ ID NO:6, respectively, were used in 25 cycles of PCR amplification.

[0085] The PCR reaction was carried out in 20 µl of a solution containing 25 ng of cDNA, 10 µM each primer, 2.5 mM dNTP and 0.25 U of Extaq DNA polymerase (product of Takara). Each PCR product was dissolved in 1.5% agarose gel stained with ethidium bromide.

[0086] The four cell lines (lane 1 = Aspc1; lane 2 = Bxpc3; lane 3 = MiaPaca2; lane 4 = PANC1) and a normal pancreatic tissue (normal pancreas, lane 5) were analyzed by RT-PCR in the above manner. The results are as shown in Fig. 2. The results for TSA305 are shown in the upper section and the results for β<sub>2</sub>-microglobulin as a control are shown in the lower section.

[0087] From the figure, it was found that the expression of TSA305 is not detected in any of cancer tissues but is detected only in normal pancreatic tissues (cf. lane 5).

#### (5) Expression of the TSA305 gene in pancreatic carcinoma (RT-PCR)

[0088] The expression of the TSA305 gene was checked in pancreatic carcinoma patient-derived samples (1T, 2T, 3T, 5T, 6T, 7T, 10T and 11T), pancreatic carcinoma (Tumor Pancreas) and normal pancreas (Invitrogen; Human Normal Pancreas) as well as a cancerous portion (23T) and a noncancerous portion (23N) of the same patient by the RT-PCR technique, as follows.

[0089] mRNA was extracted from each sample and the segment of 1581-2382 bp (801 base pairs) of TSA305 was amplified by RT-PCR and tested for detecting expression or no expression. As a concentration control, β<sub>2</sub>-microglobulin was used. The results are shown in Fig. 3.

[0090] From the figure, reduced expression or lack of expression of the TSA305 gene was observed in all pancreatic carcinoma samples as compared with the normal pancreas.

#### INDUSTRIAL APPLICABILITY

[0091] According to the present invention, the novel pancreas-specific TSA305 gene and the protein encoded thereby are provided and, by utilizing these, a technology useful, among others, in elucidating, diagnosing, preventing and treating cancers, such as pancreatic carcinoma, or malignant transformation is provided.

## SEQUENCE LISTING

<110> Otsuka Pharmaceutical Co., Ltd.

<120> TSA305 gene

<130> P98-53

<150> JP H9-3433789 and H10-126803

<151> 1997-11-28 and 1998-4-20

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 794

<212> PRT

<213> human nomal pancreas cDNA library

<400> 1

Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu

1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser

20 25 30

Leu Asp Ser Lys Thr Thr Leu Thr Ser Asp Glu Ser Val Lys Asp His

35 40 45

Thr Thr Ala Gly Arg Val Val Ala Gly Gln Ile Phe Leu Asp Ser Glu

50 55 60

Glu Ser Glu Leu Glu Ser Ser Ile Gln Glu Glu Glu Asp Ser Leu Lys

65 70 75 80

Ser Gln Glu Gly Glu Ser Val Thr Glu Asp Ile Ser Phe Leu Glu Ser

85 90 95

Pro Asn Pro Glu Asn Lys Asp Tyr Glu Glu Pro Lys Lys Val Arg Lys

100 105 110

EP 1 038 957 A1

Pro Ala Leu Thr Ala Ile Glu Gly Thr Ala His Gly Glu Pro Cys His  
115 120 125  
Phe Pro Phe Leu Phe Leu Asp Lys Glu Tyr Asp Glu Cys Thr Ser Asp  
130 135 140  
Gly Arg Glu Asp Gly Arg Leu Trp Cys Ala Thr Thr Tyr Asp Tyr Lys  
145 150 155 160  
Ala Asp Glu Lys Trp Gly Phe Cys Glu Thr Glu Glu Glu Ala Ala Lys  
165 170 175  
Arg Arg Gln Met Gln Glu Ala Glu Met Met Tyr Gln Thr Gly Met Lys  
180 185 190  
Ile Leu Asn Gly Ser Asn Lys Lys Ser Gln Lys Arg Glu Ala Tyr Arg  
195 200 205  
Tyr Leu Gln Lys Ala Ala Ser Met Asn His Thr Lys Ala Leu Glu Arg  
210 215 220  
Val Ser Tyr Ala Leu Leu Phe Gly Asp Tyr Leu Pro Gln Asn Ile Gln  
225 230 235 240  
Ala Ala Arg Glu Met Phe Glu Lys Leu Thr Glu Glu Gly Ser Pro Lys  
245 250 255  
Gly Gln Thr Ala Leu Gly Phe Leu Tyr Ala Ser Gly Leu Gly Val Asn  
260 265 270  
Ser Ser Gln Ala Lys Ala Leu Val Tyr Tyr Thr Phe Gly Ala Leu Gly  
275 280 285  
Gly Asn Leu Ile Ala His Met Val Leu Gly Tyr Arg Tyr Trp Ala Gly  
290 295 300  
Ile Gly Val Leu Gln Ser Cys Glu Ser Ala Leu Thr His Tyr Arg Leu  
305 310 315 320  
Val Ala Asn His Val Ala Ser Asp Ile Ser Leu Thr Gly Gly Ser Val  
325 330 335  
Val Gln Arg Ile Arg Leu Pro Asp Glu Val Glu Asn Pro Gly Met Asn

EP 1 038 957 A1

	340	345	350
5	Ser Gly Met Leu Glu Glu Asp Leu Ile Gln Tyr Tyr Gln Phe Leu Ala		
	355	360	365
	Glu Lys Gly Asp Val Gln Ala Gln Val Gly Leu Gly Gln Leu His Leu		
10	370	375	380
	His Gly Gly Arg Gly Val Glu Gln Asn His Gln Arg Ala Phe Asp Tyr		
	385	390	395 400
15	Phe Asn Leu Ala Ala Asn Ala Gly Asn Ser His Ala Met Ala Phe Leu		
	405	410	415
	Gly Lys Met Tyr Ser Glu Gly Ser Asp Ile Val Pro Gln Ser Asn Glu		
20	420	425	430
	Thr Ala Leu His Tyr Phe Lys Lys Ala Ala Asp Met Gly Asn Pro Val		
	435	440	445
25	Gly Gln Ser Gly Leu Gly Met Ala Tyr Leu Tyr Gly Arg Gly Val Gln		
	450	455	460
	Val Asn Tyr Asp Leu Ala Leu Lys Tyr Phe Gln Lys Ala Ala Glu Gln		
30	465	470	475 480
	Gly Trp Val Asp Gly Gln Leu Gln Leu Gly Ser Met Tyr Tyr Asn Gly		
	485	490	495
35	Ile Gly Val Lys Arg Asp Tyr Lys Gln Ala Leu Lys Tyr Phe Asn Leu		
	500	505	510
	Ala Ser Gln Gly Gly His Ile Leu Ala Phe Tyr Asn Leu Ala Gln Met		
40	515	520	525
	His Ala Ser Gly Thr Gly Val Met Arg Ser Cys His Thr Ala Val Glu		
45	530	535	540
	Leu Phe Lys Asn Val Cys Glu Arg Gly Arg Trp Ser Glu Arg Leu Met		
	545	550	555 560
50	Thr Ala Tyr Asn Ser Tyr Lys Asp Gly Asp Tyr Asn Ala Ala Val Ile		
	565	570	575

EP 1 038 957 A1

5 Gln Tyr Leu Leu Leu Ala Glu Gln Gly Tyr Glu Val Ala Gln Ser Asn  
 580 585 590  
 Ala Ala Phe Ile Leu Asp Gln Arg Glu Ala Ser Ile Val Gly Glu Asn  
 595 600 605  
 10 Glu Thr Tyr Pro Arg Ala Leu Leu His Trp Asn Arg Ala Ala Ser Gln  
 610 615 620  
 Gly Tyr Thr Val Ala Arg Ile Lys Leu Gly Asp Tyr His Phe Tyr Gly  
 15 625 630 635 640  
 Phe Gly Thr Asp Val Asp Tyr Glu Thr Ala Phe Ile His Tyr Arg Leu  
 20 645 650 655  
 Ala Ser Glu Gln Gln His Ser Ala Gln Ala Met Phe Asn Leu Gly Tyr  
 660 665 670  
 25 Met His Glu Lys Gly Leu Gly Ile Lys Gln Asp Ile His Leu Ala Lys  
 675 680 685  
 Arg Phe Tyr Asp Met Ala Ala Glu Ala Ser Pro Asp Ala Gln Val Pro  
 30 690 695 700  
 Val Phe Leu Ala Leu Cys Lys Leu Gly Val Val Tyr Phe Leu Gln Tyr  
 705 710 715 720  
 35 Ile Arg Glu Thr Asn Ile Arg Asp Met Phe Thr Gln Leu Asp Met Asp  
 725 730 735  
 Gln Leu Leu Gly Pro Glu Trp Asp Leu Tyr Leu Met Thr Ile Ile Ala  
 40 740 745 750  
 Leu Leu Leu Gly Thr Val Ile Ala Tyr Arg Gln Arg Gln His Gln Asp  
 45 755 760 765  
 Met Pro Ala Pro Arg Pro Pro Gly Pro Arg Pro Ala Pro Pro Gln Gln  
 770 775 780  
 50 Glu Gly Pro Pro Glu Gln Gln Pro Pro Gln  
 785 790  
 55

&lt;210&gt; 2

&lt;211&gt; 2382

&lt;212&gt; DNA

&lt;213&gt; human normal pancreas cDNA library

&lt;400&gt; 2

atgcgggtcc ggatagggct gacgtgctg ctgtgtgctg tgctgtgag cttggcctcg 60  
 gcgtcctcgg atgaagaagg cagccaggat gaatccttag attccaagac tactttgaca 120  
 tcagatgagt cagtaaagga ccatactact gcaggcagag tagttgctgg tcaaatattt 180  
 cttgattcag aagaatcga attagaatcc tctattcaag aagaggaaga cagccitcaag 240  
 agccaagagg gggaaagtgt cacagaagat atcagctttc tagagtctcc aaatccagaa 300  
 aacaaggact atgaagagcc aaagaaagta cggaaaccag ctttgaccgc cattgaaggc 360  
 acagcacatg gggagccctg ccacttccct ttctttttcc tagataagga gtaigtatgaa 420  
 tgtacatcag atgggagggg agatggcaga ctgtgggtgt ctacaaccta tgactacaaa 480  
 gcagatgaaa agtggggcct ttgtgaaact gaagaagagg ctgctaagag acggcagatg 540  
 caggaagcag aaatgatgta tcaaaactgga atgaaaatcc ttaatggaag caataagaaa 600  
 agccaaaaaa gagaagcata tcggtatctc caaaaggcag caagcatgaa ccataccaaa 660  
 gccctggaga gagtgtcata tgctctttta ttgtgtgatt acttgccaca gaatatccag 720  
 gcagcgagag agatgtttga gaagctgact gaggaaggct ctcccaaggg acagactgct 780  
 cttggctttc tgtatgcctc tggacttggg gttaatcaaa gtcaggcaaa ggctcttgta 840  
 tattatacat ttggagctct tgggggcaat ctaatagccc acatggtttt gggttacaga 900  
 tactgggctg gcatcggcgt cctccagagt tgtgaatctg ccttgactca ctatcgtctt 960  
 gttgccaatc atgttgctag tgaatctctg ctaacaggag gctcagtagt acagagaata 1020  
 cggctgcctg atgaagtga aaatccagga atgaacagtg gaatgctaga agaagatttg 1080  
 attcaatatt accagttcct agctgaaaaa ggtgatgtac aagcacagggt tggctcttga 1140  
 caactgcacc tgcacggagg gcgtggagta gaacagaatc atcagagagc atttgactac 1200  
 ttcaatttag cagcaaatgc tggcaattca catgccatgg cctttttggg aaagatgtat 1260  
 tcggaaggaa gtgacattgt acctcagagt aatgagacag ctctccacta cttaagaaa 1320  
 gctgtgaca tgggcaacct agttggacag agtgggcttg gaatggccta cctctatggg 1380  
 agaggagttc aagttaatta tgatctagcc ctaagtatt tccagaaaagc tgcigaacaa 1440

EP 1 038 957 A1

5 ggctgggtgg atgggcagct acagcttggg tccatgtact ataatggcat tggagtcaag 1500  
 agagattata aacaggccctt gaagiatitit aatttagctt ctcagggagg ccatactctg 1560  
 gctttctata acctagctca gatgcatgcc agtggcaccg gcgigatgcg atcatgtcac 1620  
 actgcagtgg agttgtttaa gaatglatgt gaacgaggcc gttggtctga aaggcttatg 1680  
 10 actgcctata acagctataa agatggcgat tacaatgctg cagtgatcca gtacctctc 1740  
 ctggctgaac agggctatga agtggcacia agcaatgcag cttttattct tgatcagaga 1800  
 gaagcaagca ttgtaggiga gaatgaaact tatcccagag ctttgctaca ttggaacagg 1860  
 15 gccgcctctc aaggctatac tgtggctaga attaagctcg gagactacca tttctatggg 1920  
 ttggcaccg atgtagatta tgaactgca tttattcatt accgtctggc ttctgagcag 1980  
 caacacagtg cacaagctat gttaaactcg ggatatatgc atgagaaagg actgggcatt 2040  
 20 aaacaggata ttcaccttgc gaaacgtttt tatgacatgg cagctgaagc cagcccagat 2100  
 gcacaagttc cagtcttctt agccctctgc aaattgggag tcgtctattt ctgacgtac 2160  
 atacgggaaa caaacattcg agatatgttc acccaacttg atatggacca gcttttggga 2220  
 25 cctgagtggg acctttacct catgaccatc attgcgctgc tgttgggaac agtcatagct 2280  
 tacaggcaaa ggcagcacca agacatgcct gcaccaggc ctccagggcc acggccagct 2340  
 ccaccccagc aggagggggc accagagcag cagccaccac ag 2382

30

<210> 3

<211> 7885

35

<212> DNa

<213> human normal pancreas cDNA library

<220>

40

<221> cDS

<222> (46).. (2428)

<400> 3

45

gcgaaggcga cagctctagg ggttggcacc ggccccgaga ggagg atg cgg gtc 54

Met Arg Val

I

50

cgg ata ggg ctg acg ctg ctg ctg tgt gcg gtg ctg ctg agc ttg gcc 102

55



EP 1 038 957 A1

Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu Ser Leu Ala

5                    5                    10                    15

tcg gcg tcc tcg gat gaa gaa ggc agc cag gat gaa tcc tta gat tcc                    150

Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser Leu Asp Ser

10                    20                    25                    30                    35

aag act act ttg aca tca gat gag tca gta aag gac cat act act gca                    198

Lys Thr Thr Leu Thr Ser Asp Glu Ser Val Lys Asp His Thr Thr Ala

15                    40                    45                    50

ggc aga gta gtt gct ggt caa ata ttt ctt gat tca gaa gaa tct gaa                    246

Gly Arg Val Val Ala Gly Gln Ile Phe Leu Asp Ser Glu Glu Ser Glu

20                    55                    60                    65

tta gaa tcc tct att caa gaa gag gaa gac agc ctc aag agc caa gag                    294

Leu Glu Ser Ser Ile Gln Glu Glu Glu Asp Ser Leu Lys Ser Gln Glu

25                    70                    75                    80

ggg gaa agt gtc aca gaa gat atc agc ttt cta gag tct cca aat cca                    342

Gly Glu Ser Val Thr Glu Asp Ile Ser Phe Leu Glu Ser Pro Asn Pro

30                    85                    90                    95

gaa aac aag gac tat gaa gag cca aag aaa gta cgg aaa cca gct ttg                    390

Glu Asn Lys Asp Tyr Glu Glu Pro Lys Lys Val Arg Lys Pro Ala Leu

35                    100                    105                    110                    115

acc gcc att gaa ggc aca gca cat ggg gag ccc tgc cac ttc cct ttt                    438

Thr Ala Ile Glu Gly Thr Ala His Gly Glu Pro Cys His Phe Pro Phe

40                    120                    125                    130

ctt ttc cta gat aag gag tat gat gaa tgt aca tca gat ggg agg gaa                    486

Leu Phe Leu Asp Lys Glu Tyr Asp Glu Cys Thr Ser Asp Gly Arg Glu

45                    135                    140                    145

gat ggc aga ctg tgg tgt gct aca acc tat gac tac aaa gca gat gaa                    534

Asp Gly Arg Leu trp Cys Ala Thr Thr Tyr Asp Tyr Lys Ala Asp Glu

50                    150                    155                    160

55

EP 1 038 957 A1

	aag tgg ggc ttt tgt gaa act gaa gaa gag gct gct aag aga cgg cag	582
5	Lys Trp Gly Phe Cys Glu Thr Glu Glu Glu Ala Ala Lys Arg Arg Gln	
	165 170 175	
	atg cag gaa gca gaa atg atg tat caa act gga atg aaa atc ctt aat	630
10	Met Gln Glu Ala Glu Met Met Tyr Gln Thr Gly Met Lys Ile Leu Asn	
	180 185 190 195	
	gga agc aat aag aaa agc caa aaa aga gaa gca tat cgg tat ctc caa	678
15	Gly Ser Asn Lys Lys Ser Gln Lys Arg Glu Ala Tyr Arg Tyr Leu Gln	
	200 205 210	
	aag gca gca agc atg aac cat acc aaa gcc ctg gag aga gtg tca tat	726
20	Lys Ala Ala Ser Met Asn His Thr Lys Ala Leu Glu Arg Val Ser Tyr	
	215 220 225	
	gct ctt tta ttt ggt gat tac ttg cca cag aat atc cag gca gcg aga	774
25	Ala Leu Leu Phe Gly Asp Tyr Leu Pro Gln Asn Ile Gln Ala Ala Arg	
	230 235 240	
	gag atg ttt gag aag ctg act gag gaa ggc tct ccc aag gga cag act	822
30	Glu Met Phe Glu Lys Leu Thr Glu Glu Gly Ser Pro Lys Gly Gln Thr	
	245 250 255	
	gct ctt ggc ttt ctg tat gcc tct gga ctt ggt gtt aat tca agt cag	870
35	Ala Leu Gly Phe Leu Tyr Ala Ser Gly Leu Gly Val Asn Ser Ser Gln	
	260 265 270 275	
	gca aag gct ctt gta tat tat aca ttt gga gct ctt ggg ggc aat cta	918
40	Ala Lys Ala Leu Val Tyr Tyr Thr Phe Gly Ala Leu Gly Gly Asn Leu	
	280 285 290	
	ata gcc cac atg gtt ttg ggt tac aga tac tgg gct ggc atc ggc gtc	966
45	Ile Ala His Met Val Leu Gly Tyr Arg Tyr Trp Ala Gly Ile Gly Val	
	295 300 305	
	ctc cag agt tgt gaa tct gcc ctg act cac tat cgt ctt gtt gcc aat	1014
50	Leu Gln Ser Cys Glu Ser Ala Leu Thr His Tyr Arg Leu Val Ala Asn	

55

EP 1 038 957 A1

	310	315	320	
5	cat gtt gct agt gat atc tcg cta aca gga ggc tca gta gta cag aga			1062
	His Val Ala Ser Asp Ile Ser Leu Thr Gly Gly Ser Val Val Gln Arg			
	325	330	335	
10	ata cgg ctg cct gat gaa gtg gaa aat cca gga atg aac agt gga atg			1110
	Ile Arg Leu Pro Asp Glu Val Glu Asn Pro Gly Met Asn Ser Gly Met			
	340	345	350	355
15	cta gaa gaa gat ttg att caa tat tac cag ttc cta gct gaa aaa ggt			1158
	Leu Glu Glu Asp Leu Ile Gln Tyr Tyr Gln Phe Leu Ala Glu Lys Gly			
	360	365	370	
20	gat gta caa gca cag gtt ggt ctt gga caa ctg cac ctg cac gga ggg			1206
	Asp Val Gln Ala Gln Val Gly Leu Gly Gln Leu His Leu His Gly Gly			
	375	380	385	
25	cgt gga gta gaa cag aat cat cag aga gca ttt gac tac ttc aat tta			1254
	Arg Gly Val Glu Gln Asn His Gln Arg Ala Phe Asp Tyr Phe Asn Leu			
	390	395	400	
30	gca gca aat gct ggc aat tca cat gcc atg gcc ttt ttg gga aag atg			1302
	Ala Ala Asn Ala Gly Asn Ser His Ala Met Ala Phe Leu Gly Lys Met			
	405	410	415	
35	tat tcg gaa gga agt gac att gta cct cag agt aat gag aca gct ctc			1350
	Tyr Ser Glu Gly Ser Asp Ile Val Pro Gln Ser Asn Glu Thr Ala Leu			
	420	425	430	435
40	cac tac ttt aag aaa gct gct gac atg ggc aac cca gtt gga cag agt			1398
	His Tyr Phe Lys Lys Ala Ala Asp Met Gly Asn Pro Val Gly Gln Ser			
	440	445	450	
45	ggg ctt gga atg gcc tac ctc tat ggg aga gga gtt caa gtt aat tat			1446
	Gly Leu Gly Met Ala Tyr Leu Tyr Gly Arg Gly Val Gln Val Asn tyr			
	455	460	465	
50	gat cta gcc ctt aag tat ttc cag aaa gct gct gaa caa ggc tgg gtg			1494

55

EP 1 038 957 A1

	Asp Leu Ala Leu Lys Tyr Phe Gln Lys Ala Ala Glu Gln Gly Trp Val	
	470 475 480	
5	gat ggg cag cta cag ctt ggt tcc atg tac tat aat ggc att gga gtc	1542
	Asp Gly Gln Leu Gln Leu Gly Ser Met Tyr Tyr Asn Gly Ile Gly Val	
10	485 490 495	
	aag aga gat tat aaa cag gcc ttg aag tat ttt aat tta gct tct cag	1590
	Lys Arg Asp Tyr Lys Gln Ala Leu Lys Tyr Phe Asn Leu Ala Ser Gln	
15	500 505 510 515	
	gga ggc cat atc ttg gct ttc tat aac cta gct cag atg cat gcc agt	1638
	Gly Gly His Ile Leu Ala Phe Tyr Asn Leu Ala Gln Met His Ala Ser	
20	520 525 530	
	ggc acc ggc gtg atg cga tca tgt cac act gca gtg gag ttg ttt aag	1686
	Gly Thr Gly Val Met Arg Ser Cys His Thr Ala Val Glu Leu Phe Lys	
25	535 540 545	
	aat gta tgt gaa cga ggc cgt tgg tct gaa agg ctt atg act gcc tat	1734
	Asn Val Cys Glu Arg Gly Arg Trp Ser Glu Arg Leu Met Thr Ala Tyr	
30	550 555 560	
	aac agc tat aaa gat ggc gat tac aat gct gca gtg atc cag tac ctc	1782
	Asn Ser Tyr Lys Asp Gly Asp Tyr Asn Ala Ala Val Ile Gln Tyr Leu	
35	565 570 575	
	ctc ctg gct gaa cag ggc tat gaa gtg gca caa agc aat gca gcc ttt	1830
	Leu Leu Ala Glu Gln Gly Tyr Glu Val Ala Gln Ser Asn Ala Ala Phe	
40	580 585 590 595	
	att ctt gat cag aga gaa gca agc att gta ggt gag aat gaa act tat	1878
	Ile Leu Asp Gln Arg Glu Ala Ser Ile Val Gly Glu Asn Glu Thr Tyr	
45	600 605 610	
	ccc aga gct ttg cta cat tgg aac agg gcc gcc tct caa ggc tat act	1926
50	Pro Arg Ala Leu Leu His Trp Asn Arg Ala Ala Ser Gln Gly Tyr Thr	
	615 620 625	

55

5      gtg gct aga att aag ctc gga gac tac cat ttc tat ggg ttt ggc acc      1974  
       Val Aal Arg Ile Lys Leu Gly Asp Tyr His Phe Tyr Gly Phe Gly Thr  
           630                                  635                                  640  
 10      gat gta gat tat gaa act gca ttt att cat tac cgt ctg gct tct gag      2022  
       Asp Val Asp Tyr Glu Thr Ala Phe Ile His Tyr Arg Leu Ala Ser Glu  
           645                                  650                                  655  
 15      cag caa cac agt gca caa gct atg ttt aat ctg gga tat atg cat gag      2070  
       Gln Gln His Ser Ala Gln Ala Met Phe Asn Leu Gly Tyr Met His Glu  
           660                                  665                                  670                                  675  
 20      aaa gga ctg ggc att aaa cag gat att cac ctt gcg aaa cgt ttt tat      2118  
       Lys Gly Leu Gly Ile Lys Gln Asp Ile His Leu Ala Lys Arg Phe Tyr  
           680                                  685                                  690  
 25      gac atg gca gct gaa gcc agc cca gat gca caa gtc cca gtc ttc tta      2166  
       Asp Met Ala Ala Glu Ala Ser Pro Asp Ala Gln Val Pro Val Phe Leu  
           695                                  700                                  705  
 30      gcc ctc tgc aaa ttg ggc gtc gtc tat ttc ttg cag tac ata cgg gaa      2214  
       Ala Leu Cys Lys Leu Gly Val Val Tyr Phe Leu Gln Tyr Ile Arg Glu  
           710                                  715                                  720  
 35      aca aac att cga gat atg ttc acc caa ctt gat atg gac cag ctt ttg      2262  
       Thr Asn Ile Arg Asp Met Phe Thr Gln Leu Asp Met Asp Gln Leu Leu  
           725                                  730                                  735  
 40      gga cct gag tgg gac ctt tac ctc atg acc atc att gcg ctg ctg ttg      2310  
       Gly Pro Glu Trp Asp Leu Tyr Leu Met Thr Ile Ile Ala Leu Leu Leu  
           740                                  745                                  750                                  755  
 45      gga aca gtc ata gct tac agg caa agg cag cac caa gac atg cct gca      2358  
       Gly Thr Val Ile Ala Tyr Arg Gln Arg Gln His Gln Asp Met Pro Ala  
           760                                  765                                  770  
 50      ccc agg cct cca ggg cca cgg cca gct cca ccc cag cag gag ggg cca      2406  
       Pro Arg Pro Pro Gly Pro Arg Pro Ala Pro Pro Gln Gln Glu Gly Pro  
 55

EP 1 038 957 A1

	775	780	785	
5	cca gag cag cag cca cca cag t aataggcact gggiccagcc tigtatcagtg			2458
	Pro Glu Gln Gln Pro Pro Gln			
	790			
10	acagcgaagg aagtatctg ctgggaacac tigtattiga tttaggacct tggatcagtg			2518
	gtcaccitccc agaagaggca cggcacaagg aagcattgaa ttcttaaagc tgcttagaat			2578
	ctgatgcctt tattttcagg gataagtaac tcttacctaa actgagctga atgtttgttt			2638
15	cagtgccata iggagtaaca actttcagtg gctttttttt ttcttttctg gaaacatatg			2698
	tgagacactc agaglaalgt ctactgtatc cagctatctt tctttggatc cttttggta			2758
	ttatttcagt gtgcataagt tcttaatgtc aaccatcttt aaggtattgt gcatcgacac			2818
20	taaaaactga tcagtgtaa aaaggaaaac ccagtigcaa gtttaaactg gttcgaaagt			2878
	ctgaaaatag aacttgctt ttaagttaaa aaaaaaaaaa aagctatctt gaaaatgttt			2938
	tggaaactgcg ataactgaga aacttcttac cagtccacat gcaattaaac atattcagca			2998
25	tatttgittat tttaaaaggg agggttggga ggtttcttat tggtagattgt cacacggtat			3058
	accatactcc tctcttcaa agaataaaag gccttggttaa ggagtttttt gtgagcttta			3118
	cttctttgga atggaataa cttatgcaaa accttgigaa ctgactcctt gcactaacgc			3178
30	gagtttgccc cacttactct gtaatttgct tgtttgtttt gaataataca gagccttgat			3238
	ccagaagcca gaggatggac taagtgaggag aaattagaaa acaaaacgaa ctctgggttg			3298
	ggtactacga tcacagacac agacatactt ttcttaaagt tgaagcattt gttcccagga			3358
35	tttattttac tttgcatttc tttttgcaca aagaacacat cactttcttg aattctttta			3418
	atatgaaata tcattgccag ggtatggctt acagtacta ctattatcaa tactaaaact			3478
	cagagaatca aagatggatt aaactcagtg gttagatgaaa gccaaaacct gtttgtactg			3538
40	ttctatacta ttcaggtatc tttttatttc tgatagtttt atattataat agaaagccag			3598
	ccactgctta gctatcatag tcaccatttt ctactgtta acattaggaa aatcaaggct			3658
	actatgcttc aggattgctt ggttaaatag tatgggaaaa aaactgaaga gtttcaacat			3718
45	aattacacac gtgaaataat tacagcttaa actgaatttg tatttcattt tattgtcaga			3778
	tgggtgtgtt caccagctg tatctgtct gagactgcat tegtatctga gcaggitttc			3838
50	tatgcctact gatgtcagta tgtttalact aaccttcattg cttttttccc agaateccctc			3898
	atctgccaga aaacttgaaa agtttattgc ttgtagagtt gtactgcttt gatttttgaa			3958

55

gtiggggtag tagttagaac tagatttaac tagtctataa tgaacatgaa ggcttttata 4018  
 tatgaagtig tataccitit tigtitlaga gaattatggg aaacctggta agcaaaactt 4078  
 5 tcttcccaga taattgcttc caaatlcgaa gagttagtca ccaagagagc catatgtatg 4138  
 aaagcgtatc tgtgaaaggt aggaaacita cccccctaa gtgtaatgtt gctttaggca 4198  
 10 actcttgtaa atagttagac ttgttgggc tcttacaatgt agagatttga gtgcagttgg 4258  
 tacagtactt tgggtgtctc accactgtcc ctctccccg ctccaataa agtgtaatcc 4318  
 acggttagcag ccacacttcc ttcagaagga actgttataa tttattttaa agttgaaaaa 4378  
 15 ccaccaaga tgactacca ctttcacitit tttcttctg ccatccacc tcaitttccc 4438  
 tttagcaaga tttttatate taactttcct tccctccatt gactacgtgc tttgagaaaa 4498  
 catttcttaa aacagtgtgt gccacctaa gctggatggg aaagtgcagt ctgttgttgc 4558  
 20 atataaaaaa cacacttctt attagtttac ccacttgcct tttctatitg ttaatgttct 4618  
 gaatttccct tcttggctt gtttctactt catittaaacc ctgggtcact tgcgtccagc 4678  
 agtttgtgaa tgggtgtctt caataactt agttcttatg gcttcactta aagactgtct 4738  
 25 caaaaatact ttgtctctt ctctttttt gtctatggga catgttacct aagcaaatag 4798  
 gatttgggtt tggtttttct cctaaaaata tgcataatc ttacctaatc aaatggcatc 4858  
 catttgaata aaatgacaat aactaaagct agttaatgtc agtgacattt aactaactcc 4918  
 30 aggattcagg agtttttaag ttagaattta gatttaacag atagagtgtg gcttcatttg 4978  
 tccaiggtag cccatctctc ctaagacctt tctagtcgt tcttcttgc ttcgaacttg 5038  
 atgacagtta aacctgttt agtattctct tgtgcatitg gttgttgggt tagccgactg 5098  
 35 tcttgaaact attcattttg ctctagttt tattttacag aggtagcatt ggtgggtttt 5158  
 ttttttttt tctgtctctg tgttgaagt ttcatgttct gtttcttagg taaggcttat 5218  
 ttttgattag cagicaatgg caaagaaaaa glaatcaaa gatgacttct tttcaaatg 5278  
 40 tatggccctt ttattgcact ttaactcag atgaatttat aaattattaa tcttgatact 5338  
 aaggatttgt tacttttttg catattaggt taatttttac ctacatgtg agagtcttac 5398  
 cactaagcca tctgtctct gtactgttgg gaagtttgg aaacctctgc cagtgtctg 5458  
 45 gtagatgact gatgatttat ttaagagcc gttgatgcct ccaggaaact taagtatttt 5518  
 attaatatat atataggaat ttttttttat ttgtcttgt ctctctctc ctctttttat 5578  
 50 cctcalttc attcttcaaa ccagtgtttt ggaagtatgc atgcaggcct ataaatgaaa 5638  
 aacacaattc tttatgtgta tagcatgtgt attaatgtct aactacatac gcaaaaactt 5698



cclttacaga ggltcggact aacatttcac atgcacattt caaaacaaga lgtgtcalga 5758  
 5 aaacagcccc ttaccctgcc aagacaagca gggctatatt tcagtgcag ctggatattt 5818  
 tgtttctgaa agtgaatctc ataatatata tatgtattac acattattat gactagaagt 5878  
 atgtaagaaa tgaicagaac aaaagaaaaat ttctattttc atgcaaataat ttttcatcag 5938  
 10 tcatcactct caaatataaa ttaaaatata acactcctga atgcctgagg cagcatctgg 5998  
 attttaaatg tgtggatctc atigaaaaga agctctccac ccacttgga tttcaagaaa 6058  
 atttaaaacg atcccaagga aagatgattt gtagttaa gigactgcac aagtaaaagt 6118  
 15 ccaatgttgt gtgcatgaaa aggattcctt ggittatgtc agggaatcat ctcacatgct 6178  
 gtttttccct tttggtttga gaaacaggct gacactattc tctttgatta gaaaataaac 6238  
 tcataaaact cataatgttg atataatcaa gatgttaacc actataaata tgtagaagag 6298  
 20 gaagttttta atagacctta agctggcatt gigaaggaac accatggtag actctttttg 6358  
 gtaatggtat tttgtattta atgaaatgca gtataaaggi tggigaagtg taataataat 6418  
 tgtgtaaaca aatcctgttt aatagaagag atgtacagaa tggitttggg actgtatctt 6478  
 25 gaaacttgtg aaataaagat tccacttttg gttatcctgt atgctgtaat ataccacaac 6538  
 caagcacctt tccagacag acttttttta agcigaatga atccaatttt ttaatgtttt 6598  
 ttggaaattc agaagcttct gaaaacattc acttgggca atttgaattt atctttcatt 6658  
 30 ttaaacttct gaaattcaga tttttacaag tccaatatig ccttagggag aacatgaatt 6718  
 tgctaagaaa tgttatcttt taaatctctg atatctttgt ctggaagcag ccttgatatg 6778  
 tagtaagcgt gattcacttt agcctgatta taatattatt tatctaaagt ttgtttatgc 6838  
 35 attgccttgt cccaggaatt ttttaagagg acttgcagag acacgtacca cacagtaaca 6898  
 tttagactaa atatgctctg agtaaaggag aaatgaaaaa atattaaatc aagagtgaac 6958  
 atgtacacaa agtgcaattg gaagtgggct acaaatttag ccccagctt cccagcaggc 7018  
 40 aactcaaaga ggtaactgag gtaaaatgtt ccagctcaga agcattggat cttggataaa 7078  
 aagcctacat gatgcaact gtggcaactg agatgtcaga tctcaagatc tcaaattgta 7138  
 ctgttgggag cacagtcagt gacccagat gaccttgaat gacctaaaag ttgtggggga 7198  
 45 agtcggatgt cagagcctta acaccagcag gtgaccatcc aacctggggc aatgcctgcc 7258  
 tgttaccac ttagcctctt tctggcaagt cattagaatg tcttccatct tcatggctg 7318  
 caacttgatg agctacagcc tctttcctaa ctctctttat gatgtatgt taggttgggt 7378  
 50 ataccagctt ggaagtatgc ttagattaaag ttacagcaga tacacaaatt agatgaagt 7438

aaaaaaaatc agaatttcig tagtagaaac tacgaaaaat aaaaaggaaa gtttttactt 7498  
 tttgggiatt tttttacgaa taagaaaaag tgagcgtaa tcagttcaaa aggaggtact 7558  
 5 gctgtgiaat gggctttgta cgttccttct cagttcactt acgtcactac ttcgccaatca 7618  
 aattgaacaa gcttttaatt agatcctgaa aattcactat gctagtagtt tattggtagt 7678  
 10 attatatatt gagtagaact ctgattttcc ctagaggcca aattcctttt atctgggtta 7738  
 atttccttta aacataacaa tgtaaatgct gaattgtata ttaaatacca tttctaaaaa 7798  
 ccacacaatt tttctcatg taagttgagt ggaatgtggg tagttaactg aatttggaat 7858  
 15 gttcatataa ataatttggt gctgctc 7885

<210> 4

<211> 10

<212> DNA

<213> Primer sequence for PCR of TSA305

<400> 4

gactgacac

10

<210> 5

<211> 28

<212> DNA

<213> Primer sequence for PCR of TSA305

<400> 5

gacggatcc aggaggaatgc gggatcgg

28

<210> 6

<211> 30

<212> DNA

<213> Primer sequence for PCR of TSA305

<400> 6


gacccatcag ttactgtggt ggctgctgct

30

Claims

1. A pancreas-specific gene which comprises a base sequence coding for a protein having the amino acid sequence shown under SEQ ID NO:1.
2. A gene as claimed in Claim 1 which is a human gene.
3. A gene as claimed in Claim 1 which is defined by the base sequence shown under SEQ ID NO:2.
4. A gene as claimed in Claim 3 which is a human gene.
5. A pancreas-specific gene which is either of the polynucleotides defined below under (a) and (b):
  - (a) a polynucleotide containing the whole or part of the nucleotide sequence shown under SEQ ID NO:2;
  - (b) a polynucleotide capable of hybridizing with a DNA having the nucleotide sequence shown under SEQ ID NO:2 under stringent conditions.
6. A gene as claimed in Claim 5 which is a human gene.
7. A gene as claimed in Claim 5 which is a DNA fragment usable as a specific probe or specific primer in detecting the pancreas-specific gene defined in Claim 1.
8. A pancreas-specific protein having the amino acid sequence shown under SEQ ID NO:1.
9. An antibody capable of binding to the pancreas-specific protein defined in Claim 8.

Fig. 1



F i g. 2





Fig. 3



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/05306


<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl. <sup>6</sup> C12N15/12, C07K14/435, C07K16/18		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl. <sup>6</sup> C12N15/12, C07K14/435, C07K16/18		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) SwissProt/PIR/GeneSeq, Genbank/EMBL/DBJ/GeneSeq		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Barth Grant et al., "The <i>Caneorhabditis elegans sel-1</i> gene, a negative regulator of <i>lin-12</i> and <i>glp-1</i> , encodes a predicted extracellular protein", Genetics (1996) Vol. 143, No. 1 p.237-247	1-9
A	Barth Grant et al., "Structure, function, and expression of SEL-1, a negative regulator of LIN-12 and GLP-1 in <i>C. elegans</i> ", Development (1997) Vol. 124, No. 3 p.637-644	1-9
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 3 March, 1999 (03. 03. 99)		Date of mailing of the international search report 16 March, 1999 (16. 03. 99)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)





Fig. 1



F i g. 2




Fig. 8

